The therapeutic role of RAS blockade in chronic heart failure. - Wikidata - awgldk - TriplyDB

The therapeutic role of RAS blockade in chronic heart failure.

The therapeutic role of RAS blockade in chronic heart failure.

http://www.wikidata.org/entity/Q34915602

about

Cardiac defects contribute to the pathology of spinal muscular atrophy models Local angiotensin II aggravates cardiac remodeling in hypertension.Cardiac insulin resistance and microRNA modulators.A Food-Derived Flavonoid Luteolin Protects against Angiotensin II-Induced Cardiac Remodeling.Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.Group V secretory phospholipase A2 enhances the progression of angiotensin II-induced abdominal aortic aneurysms but confers protection against angiotensin II-induced cardiac fibrosis in apoE-deficient mice.Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.Protective Role of Ramipril and Candesartan against Myocardial Ischemic Reperfusion Injury: A Biochemical and Transmission Electron Microscopical Study.Luteolin: A Flavonoid that Has Multiple Cardio-Protective Effects and Its Molecular Mechanisms.Effects of sex and ovarian hormones on the initial renal sympathetic nerve activity response to myocardial infarction.Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells.

P2860

Q28290032-B8A19A2E-0411-45DB-9F6B-7A8ED7257DDC Q34357832-06170722-8966-4BFF-B823-64256F337022 Q35251097-EB5366FF-0A54-4AF8-A119-08FB7831F567 Q35761216-8B515003-5C2F-4FD9-982A-9BE60B4AC960 Q35789287-6FCE7B71-4EB6-4527-87A6-E1429288142B Q36204176-36291221-40E3-475E-B0D5-624E0488EA4A Q36310106-B7D3E5F6-E4FA-45C0-86B1-04210FD9DDB9 Q36726341-5844664C-3602-48D2-A457-E02493EFA6F4 Q39217232-66E7E2DF-8482-4EC9-BFDC-9ED5C3FF2A93 Q47163455-864D445D-430A-49AD-A3A8-6BE6E0D0731F Q51341583-44944212-7E92-454E-958D-F09F3B856F98 Q54640381-863746EC-DAEC-480B-997D-898AC4558595

P2860

The therapeutic role of RAS blockade in chronic heart failure.

http://www.wikidata.org/entity/Q34915602

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The therapeutic role of RAS blockade in chronic heart failure.

@ast

The therapeutic role of RAS blockade in chronic heart failure.

@en

The therapeutic role of RAS blockade in chronic heart failure.

@nl

type

label

The therapeutic role of RAS blockade in chronic heart failure.

@ast

The therapeutic role of RAS blockade in chronic heart failure.

@en

The therapeutic role of RAS blockade in chronic heart failure.

@nl

prefLabel

The therapeutic role of RAS blockade in chronic heart failure.

@ast

The therapeutic role of RAS blockade in chronic heart failure.

@en

The therapeutic role of RAS blockade in chronic heart failure.

@nl

P1433

Q34915602-61BC892B-36FB-40E5-8104-230CBA80C465

P1476

Q34915602-6D985945-66FF-469D-A229-E5824FB006AF

P2093

Q34915602-595A988F-4298-4B2B-9896-CB53E111BF8D

Q34915602-A04CD669-4FCC-47A0-A116-1CEA6EA563EF

P2860

Q34915602-032C8426-748B-41B4-A8FC-2377151FBF31

Q34915602-053FEBED-C53A-4733-9347-8A25F19F71E4

Q34915602-080C902F-0D1C-40F8-B9EA-8EF38D062DF1

Q34915602-0B198501-10D3-4464-A7C3-2A5A7E3B023F

Q34915602-11A06FD8-31F7-4963-A2C9-765156AD3D7B

Q34915602-1408CFC4-608F-4BEA-816A-F436095ECB36

Q34915602-14CAF8AB-D213-4B0E-B739-5F828F8EA5AC

Q34915602-1ED51F32-8913-41ED-966B-60748A96C81D

Q34915602-227676E2-1077-46A9-B991-68C80AB5A61A

Q34915602-23D9CE38-91DF-4F7D-91D4-59B98B1BE6AE

P304

Q34915602-21C66514-0B60-48AC-B3BC-B630FCA943CD

P31

Q34915602-8634BA1B-EBC8-4A57-AE36-BD72EB780A2A

P356

Q34915602-31036232-A767-4040-A7EB-DD00966B8D36

P433

Q34915602-0A147E41-CD40-477D-A339-DE6518A234AB

P478

Q34915602-9B4FFA2A-18DE-4CD3-A1F6-AF09D3E0C1AE

P577

Q34915602-F3B9234A-14B5-4886-BC2E-BFE2D1C90DBD

P698

Q34915602-1AD79B8F-D890-4FC4-B457-1047CA86E642

P921

Q34915602-082283C9-1F38-49EA-9125-E2594EC5B3B7

P356

1753944708091777

P1433

Therapeutic advances in cardiovascular disease

P1476

The therapeutic role of RAS blockade in chronic heart failure.

@en

P2093

Christian M Werner

http://www.w3.org/2001/XMLSchema#string

Michael Böhm

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Effect of ramipril on the incidence of diabetes.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

P304

167-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944708091777

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19124420

http://www.w3.org/2001/XMLSchema#string

P921